Results

4 stories for“TRIUMPH trial results”

TRIUMPH-2 and TRIUMPH-3 read out in July, following TRIUMPH-1 in May. Across the programme the triple agonist has produced weight loss in a range no approved obesity drug has reached, with a filing due in early 2027.

Aug 11, 2026

Health

Retatrutide: The Triple Agonist Still Proving Itself

Retatrutide just posted phase 3 weight loss data hitting three hormone receptors at once. Here is what is confirmed and what remains unproven.

May 27, 2026

Health

One Receptor, Two, or Three: Comparing Semaglutide, Tirzepatide and Retatrutide

Ozempic, Mounjaro and the drug that has not arrived yet are not three versions of the same thing. They hit different receptors, produce different results, and suit different people.

Aug 11, 2026

Results

Retatrutide's Phase 3 Run Is Nearly Complete. The Numbers Are the Largest Yet

Retatrutide: The Triple Agonist Still Proving Itself

One Receptor, Two, or Three: Comparing Semaglutide, Tirzepatide and Retatrutide

Results

Retatrutide's Phase 3 Run Is Nearly Complete. The Numbers Are the Largest Yet

Retatrutide: The Triple Agonist Still Proving Itself

One Receptor, Two, or Three: Comparing Semaglutide, Tirzepatide and Retatrutide